This brief report examines the extent to which community-based treatment and integration support are provided for people living with mental illness across 15 selected Asia-Pacific economies. Some of the key findings are discussed in light of the diversity of economies and cultural contexts.
BJPSYCH... INTERNATIONALVOLUME 15 NUMBER 4 NOVEMBER 201
more
Evaluating the Return on Investment of Scaling Up Treatment for Depression, Anxiety, and Psychosis
Web annex 6: Injectable prostaglandins versus
placebo or no treatment
Evidence to Decision Framework
The mission of this Center is to close the treatment gap for people living with mental, neurological and substance use disorders in low resource settings
AWaRe – a new WHO tool to help countries improve antibiotic treatment, increase access and reduce resistance. We can reduce or even reverse antibiotic resistance by using antibiotics more responsibly. But how do we do that and still ensure that patients are treated effectively?WHO has developed a ...tool to help global, regional and national decision-making on which antibiotics to use when. The tool indexes the most effective antibiotics into three groups – ACCESS, WATCH, RESERVE (AWaRe for short). Evidence shows that to optimize use of antibiotics and reduce resistance, countries should increase the proportion of ACCESS antibiotics to correspond to at least 60% of total national consumption.
more
Clinical Guidelines. Diagnosis and Treatment Manual.
Web annex 5: Oxytocin and ergometrine versus placebo or no treatment
Evidence to decision framework
The present booklet is about gender-responsive substance abuse treatment services for women. It is part of the United Nations Office on Drugs and Crime (UNODC) project to develop tools to support the development and improvement of substance abuse treatment services, based on evidence from the litera...ture and case studies that illustrate practical experiences and lessons learned in providing substance abuse treatment services in various regions of the world.
more
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of... Buruli ulcer everywhere. However, this finding does not mean that
Buruli ulcer is cured at 8 weeks.
more
Recognition, Assessment and Treatment
National Clinical Guideline Number 159
Protocol for the management of specialized centres for the treatment of people with alcohol and other drug abuse problems (CETAD) in the framework of the COVID-19 pandemic. Version 1.
Unstable settings present challenges for the effective provision of antiretroviral treatment (ART). In this paper, we summarize the experience and results of providing ART and implementing contingency plans during acute instability in the Central African Republic (CAR) and Yemen.
For 100 cases among which 60 cases of children ≥ 5 years old and 40 cases of children < 5 years old and adults.
The new Pneumonia kit 2020 is specially designed to provide sufficient child-size antibiotics to treat pneumonia, targeting children under 5 years of age. It aims to provide life-savi...ng treatment based on the WHO protocols WHO treatment guidance Pneumonia should be treated with antibiotics.
The antibiotic of choice is amoxicillin dispersible tablets. Most cases of pneumonia require oral antibiotics, which are often prescribed at a health centre.
more
Africa Centers for Disease Control and Prevention (Africa CDC) is aware of the media releases of the preliminary results of a large randomized clinical trial conducted in the United Kingdom, which included dexamethasone, a corticosteroid, as one of the drugs used for the treatment of COVID-19 patien...ts. The investigators reported that administration of oral or injectable dexamethasone resulted in about one-third reduction in mortality among COVID-19 patientsi that required mechanical ventilation and about one-fifth for patients requiring oxygen.
more
The Lancet olume 395, ISSUE 10232, P1259-1267, April 18, 2020. Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifa...mpicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8) is highly effective, but streptomycin injections are painful and potentially harmful. We aimed to compare the efficacy and tolerability of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8) with that of RS8 for treatment of early Buruli ulcer lesions.
more
Sleeping sickness is controlled by case detection and treatment but this often only reaches less than 75% of the population. Vector control is capable of completely interrupting HAT transmission but is not used because of expense. We conducted a full scale field trial of a refined vector control tec...hnology. From preliminary trials we determined the number of insecticidal tiny targets required to control tsetse populations by more than 90%. We then carried out a full scale, 500 km2 field trial covering two HAT foci in Northern Uganda (overall target density 5.7/km2). In 12 months tsetse populations declined by more than 90%. A mathematical model suggested that a 72% reduction in tsetse population is required to stop transmission in those settings. The Ugandan census suggests population density in the HAT foci is approximately 500 per km2. The estimated cost for a single round of active case detection (excluding treatment), covering 80% of the population, is US$433,333 (WHO figures). One year of vector control organised within country, which can completely stop HAT transmission, would cost US$42,700. The case for adding this new method of vector control to case detection and treatment is strong. We outline how such a component could be organised.
more
WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19.
We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ...with non-severe COVID-19 as the treatment brought no benefits, and could even prove harmful. Treatment should be under supervision of a clinician.
Corticosteroids are listed in the WHO model list of essential medicines, readily available globally at a low cost. WHO encourages countries to maintain sufficient stocks of corticosteroids to treat COVID-19 and the other disease for which they are effective, while not maintaining excessive stocks which could deny other countries access.
more
Recommendations for Tuberculosis Screening Before Initiation of TNF-α-Inhibitor Treatment in Rheumatic Diseases
Diel R et al. Empfehlungen für das Tuberkulosescreening vor Gabe von TNF-α-Inhibitoren… Pneumologie 2009; 63: 329–334
Violence Against Women and HIV/AIDS Prevention and Treatment
Web annex 2: Carbetocin versus placebo or no treatment
Evidence to decision framework